Precision BioSciences Inc
DTIL4.490USD
-0.030-0.66%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
54.25MMarket Cap
LossP/E TTM
More Details of Precision BioSciences Inc Company
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
Precision BioSciences Inc Info
Ticker SymbolDTIL
Company namePrecision BioSciences Inc
IPO dateMar 28, 2019
CEOAmoroso (Michael)
Number of employees108
Security typeOrdinary Share
Fiscal year-endMar 28
Address302 E Pettigrew St Ste A100
CityDURHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27701-2393
Phone19193145512
Websitehttps://precisionbiosciences.com/
Ticker SymbolDTIL
IPO dateMar 28, 2019
CEOAmoroso (Michael)
Company Executives of Precision BioSciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Amoroso
Mr. Michael Amoroso
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
115.58K
+5.51%
Ms. Melinda Brown
Ms. Melinda Brown
Independent Director
Independent Director
21.96K
+6.81%
Mr. Geno J. Germano
Mr. Geno J. Germano
Independent Director
Independent Director
20.88K
+88.87%
Ms. Cindy Atwell
Ms. Cindy Atwell
Chief Development and Business Officer
Chief Development and Business Officer
--
--
Dr. Jeff Smith
Dr. Jeff Smith
Chief Research Officer
Chief Research Officer
--
--
Ms. Shari Lisa Pire
Ms. Shari Lisa Pire
Independent Director
Independent Director
--
--
Mr. Dario Scimeca
Mr. Dario Scimeca
General Counsel, Secretary
General Counsel, Secretary
--
--
Dr. Stanley R. Frankel, M.D.
Dr. Stanley R. Frankel, M.D.
Independent Director
Independent Director
--
--
Mr. Kevin J. Buehler
Mr. Kevin J. Buehler
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Alex Kelly
Mr. Alex Kelly
Chief Financial Officer
Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Amoroso
Mr. Michael Amoroso
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
115.58K
+5.51%
Ms. Melinda Brown
Ms. Melinda Brown
Independent Director
Independent Director
21.96K
+6.81%
Mr. Geno J. Germano
Mr. Geno J. Germano
Independent Director
Independent Director
20.88K
+88.87%
Ms. Cindy Atwell
Ms. Cindy Atwell
Chief Development and Business Officer
Chief Development and Business Officer
--
--
Dr. Jeff Smith
Dr. Jeff Smith
Chief Research Officer
Chief Research Officer
--
--
Ms. Shari Lisa Pire
Ms. Shari Lisa Pire
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bleichroeder LP
4.69%
Lynx1 Capital Advisors LLC
4.55%
Readout Capital LP
3.00%
Tang Capital Management, LLC
2.85%
The Vanguard Group, Inc.
2.15%
Other
82.75%
Shareholders
Shareholders
Proportion
Bleichroeder LP
4.69%
Lynx1 Capital Advisors LLC
4.55%
Readout Capital LP
3.00%
Tang Capital Management, LLC
2.85%
The Vanguard Group, Inc.
2.15%
Other
82.75%
Shareholder Types
Shareholders
Proportion
Investment Advisor
13.38%
Individual Investor
4.78%
Hedge Fund
4.54%
Venture Capital
3.02%
Investment Advisor/Hedge Fund
2.59%
Corporation
1.81%
Research Firm
0.08%
Bank and Trust
0.03%
Other
69.78%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
128
5.41M
36.99%
--
2025Q3
137
5.41M
70.59%
+188.72K
2025Q2
142
5.28M
63.35%
+463.42K
2025Q1
147
4.82M
55.66%
-1.05M
2024Q4
161
3.99M
54.59%
+521.68K
2024Q3
175
3.44M
57.36%
+159.09K
2024Q2
201
3.28M
66.52%
+709.00
2024Q1
278
3.30M
37.60%
+696.74K
2023Q4
293
1.28M
57.49%
+78.37K
2023Q3
307
1.20M
61.80%
-310.58K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bleichroeder LP
1.07M
9.12%
+1.06M
+8801.22%
Jun 30, 2025
Lynx1 Capital Advisors LLC
1.04M
8.79%
+270.00K
+35.25%
Jun 30, 2025
Readout Capital LP
686.44K
5.82%
-233.56K
-25.39%
Jun 30, 2025
Tang Capital Management, LLC
653.65K
5.55%
-19.68K
-2.92%
Jun 30, 2025
The Vanguard Group, Inc.
405.35K
3.44%
+124.27K
+44.21%
Jun 30, 2025
Novartis Pharma AG
413.58K
3.51%
--
--
Jun 30, 2025
Benjamin (Weinstein)
395.49K
3.36%
+395.49K
--
Mar 18, 2025
Smith (Matthew)
212.87K
1.81%
+117.14K
+122.36%
Jun 30, 2025
Renaissance Technologies LLC
80.28K
0.68%
-2.70K
-3.25%
Jun 30, 2025
Boothbay Fund Management, LLC
200.00K
1.7%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
DFA Dimensional US Small Cap Value ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0%
DFA Dimensional US Small Cap Value ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 09, 2024
Merger
30→1
Feb 09, 2024
Merger
30→1
Feb 09, 2024
Merger
30→1
Feb 09, 2024
Merger
30→1
Date
Type
Ratio
Feb 09, 2024
Merger
30→1
Feb 09, 2024
Merger
30→1
Feb 09, 2024
Merger
30→1
Feb 09, 2024
Merger
30→1
FAQs
Who are the top five shareholders of Precision BioSciences Inc?
The top five shareholders of Precision BioSciences Inc are:
Bleichroeder LP holds 1.07M shares, accounting for 9.12% of the total shares.
Lynx1 Capital Advisors LLC holds 1.04M shares, accounting for 8.79% of the total shares.
Readout Capital LP holds 686.44K shares, accounting for 5.82% of the total shares.
Tang Capital Management, LLC holds 653.65K shares, accounting for 5.55% of the total shares.
The Vanguard Group, Inc. holds 405.35K shares, accounting for 3.44% of the total shares.
Bleichroeder LP holds 1.07M shares, accounting for 9.12% of the total shares.
Lynx1 Capital Advisors LLC holds 1.04M shares, accounting for 8.79% of the total shares.
Readout Capital LP holds 686.44K shares, accounting for 5.82% of the total shares.
Tang Capital Management, LLC holds 653.65K shares, accounting for 5.55% of the total shares.
The Vanguard Group, Inc. holds 405.35K shares, accounting for 3.44% of the total shares.
What are the top three shareholder types of Precision BioSciences Inc?
The top three shareholder types of Precision BioSciences Inc are:
Bleichroeder LP
Lynx1 Capital Advisors LLC
Readout Capital LP
Bleichroeder LP
Lynx1 Capital Advisors LLC
Readout Capital LP
How many institutions hold shares of Precision BioSciences Inc (DTIL)?
As of 2025Q4, 128 institutions hold shares of Precision BioSciences Inc, with a combined market value of approximately 5.41M, accounting for 36.99% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -33.60%.
What is the biggest source of revenue for Precision BioSciences Inc?
In --, the -- business generated the highest revenue for Precision BioSciences Inc, amounting to -- and accounting for --% of total revenue.
